Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Willis L, Hayes D Jr, Mansour HM.

Lung. 2012 Jun;190(3):251-62. doi: 10.1007/s00408-011-9360-x. Epub 2012 Jan 25. Review.

PMID:
22274758
2.

Recent advances in liposomal dry powder formulations: preparation and evaluation.

Misra A, Jinturkar K, Patel D, Lalani J, Chougule M.

Expert Opin Drug Deliv. 2009 Jan;6(1):71-89. doi: 10.1517/17425240802652309 . Review.

PMID:
19236209
3.

Dry powder inhalers in COPD, lung inflammation and pulmonary infections.

Muralidharan P, Hayes D Jr, Mansour HM.

Expert Opin Drug Deliv. 2015 Jun;12(6):947-62. doi: 10.1517/17425247.2015.977783. Epub 2014 Nov 12. Review.

PMID:
25388926
4.

Pulmonary drug delivery by powder aerosols.

Yang MY, Chan JG, Chan HK.

J Control Release. 2014 Nov 10;193:228-40. doi: 10.1016/j.jconrel.2014.04.055. Epub 2014 May 9. Review.

PMID:
24818765
5.

Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.

Park CW, Li X, Vogt FG, Hayes D Jr, Zwischenberger JB, Park ES, Mansour HM.

Int J Pharm. 2013 Oct 15;455(1-2):374-92. doi: 10.1016/j.ijpharm.2013.06.047. Epub 2013 Jun 29.

PMID:
23820131
6.

Dry powder inhalers for pulmonary drug delivery.

Frijlink HW, De Boer AH.

Expert Opin Drug Deliv. 2004 Nov;1(1):67-86. Review.

PMID:
16296721
7.

Pharmaceutical aerosols for the treatment and prevention of tuberculosis.

Hanif SN, Garcia-Contreras L.

Front Cell Infect Microbiol. 2012 Sep 7;2:118. doi: 10.3389/fcimb.2012.00118. eCollection 2012. Review.

8.

Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.

Costabile G, d'Angelo I, d'Emmanuele di Villa Bianca R, Mitidieri E, Pompili B, Del Porto P, Leoni L, Visca P, Miro A, Quaglia F, Imperi F, Sorrentino R, Ungaro F.

J Control Release. 2016 Sep 28;238:80-91. doi: 10.1016/j.jconrel.2016.07.029. Epub 2016 Jul 19.

PMID:
27449745
9.

Inhaled Formulation Design for the Treatment of Lung Infections.

Garcia-Contreras L, Yadav KS.

Curr Pharm Des. 2015;21(27):3875-901. Review.

PMID:
26290199
11.

How can we bring high drug doses to the lung?

Claus S, Weiler C, Schiewe J, Friess W.

Eur J Pharm Biopharm. 2014 Jan;86(1):1-6. doi: 10.1016/j.ejpb.2013.11.005. Epub 2013 Dec 1. Review.

PMID:
24300444
13.

Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.

Lin YW, Wong J, Qu L, Chan HK, Zhou QT.

Curr Pharm Des. 2015;21(27):3902-16. Review.

PMID:
26290193
14.

The role of particle properties in pharmaceutical powder inhalation formulations.

Chew NY, Chan HK.

J Aerosol Med. 2002 Fall;15(3):325-30. Review.

PMID:
12396421
15.

Liposomal dry powders as aerosols for pulmonary delivery of proteins.

Lu D, Hickey AJ.

AAPS PharmSciTech. 2005 Dec 21;6(4):E641-8.

16.

Development of dry powder inhalers.

Chougule MB, Padhi BK, Jinturkar KA, Misra A.

Recent Pat Drug Deliv Formul. 2007;1(1):11-21. Review.

PMID:
19075871
17.

A review of co-milling techniques for the production of high dose dry powder inhaler formulation.

Lau M, Young PM, Traini D.

Drug Dev Ind Pharm. 2017 Aug;43(8):1229-1238. doi: 10.1080/03639045.2017.1313858. Epub 2017 Apr 19.

PMID:
28367654
18.

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Prime D, de Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, Baines A, Moore A, Brealey N, Moynihan J.

J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):486-97. doi: 10.1089/jamp.2015.1224. Epub 2015 Sep 15.

19.
20.

Inhalable nanoparticulate powders for respiratory delivery.

Muralidharan P, Malapit M, Mallory E, Hayes D Jr, Mansour HM.

Nanomedicine. 2015 Jul;11(5):1189-99. doi: 10.1016/j.nano.2015.01.007. Epub 2015 Feb 4. Review.

Supplemental Content

Support Center